Article
19 Aug 2025
ASC Gives Guidance On Canada's Takeover Bid Regime And Directors' Duties In Cease-Trading A Poison Pill
Jean-Pierre Chamberland
Popular Topics
Corporate/Commercial Law
Food, Drugs, Healthcare, Life Sciences
AUTHORS CONTENT
Article
26 May 2025
"Hell Or High Water" Clauses In M&A: Delaware Gives Guidance
Article
21 Apr 2025
Board Governance Amid Trade Uncertainty: Strategic Considerations For Directors In Canada
Article
26 Feb 2025
Proposed Regulations To Mitigate Drug And Device Shortages In Canada
Article
18 Jul 2024
Fairness Opinions In Canadian Public M&A
Article
01 Feb 2024
IPOs In Canada: Getting Ready To Go Public
Article
19 Jan 2024
Fasken M&A Year In Review 2023
Article
23 Nov 2023
IPOs And Going Public In Canada
Article
09 Nov 2023
New AI Technologies Push Health Canada To Modernize Its Medical Device Pre-Market Guidance Framework
Article
15 Sep 2023
Bill 15: Minister Of Health Proposes Amendments To The Specific Medical Necessity Measure
Article
18 Aug 2023
ESG In Public M&A: What's Market? – Part 2
Article
07 Aug 2023
ESG In Public M&A: What's Market? – Part 1
Article
20 Feb 2023
Re-Writing The Unwritten: Fasken Submits Recommendations Regarding The TSX's Proposed Prospectus Offering Amendments
Article
12 Dec 2022
Capital Markets : 6 Highlights In 2022
Article
08 Apr 2021
The Quebec Patient Financial Assistance Ban Is Here
Article
21 May 2020
Canadian Securities Regulators Provide Guidance On Public Disclosure In Time Of COVID-19
Article
08 Apr 2013
A New Era In Canadian Defensive Tactics? Canadian Securities Regulators Publish Competing Proposals On Poison Pills And Defensive Tactics